Pharmacogenetics and postoperative pain: A new approach to improve acute pain management

Minerva Anestesiologica

Volumn 76, Issue 11, 2010, Pages 937-944

  Allegri, M ^a   de gregori, M ^a,b   Niebel, T ^a,b   Minella, C ^a   Tinelli, C ^a   Govoni, S ^b   Regazzi, M ^a   Braschi, A ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Acute pain; Drug interactions; Opioids; Pharmacogenetics; Polymorphisms; Postoperative pain

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CLOMIPRAMINE; DESIPRAMINE; DIAMORPHINE; DIAZEPAM; DICLOFENAC; FENTANYL; HYDROMORPHONE; IMIPRAMINE; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; LORAZEPAM; METHADONE; MORPHINE; MYCOPHENOLIC ACID; NALOXONE; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; OPIATE; OXYCODONE; OXYMORPHONE; TACROLIMUS; TAMOXIFEN; UNINDEXED DRUG; VALPROIC ACID;

ANALGESIA; CHRONIC PAIN; DRUG ANTAGONISM; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; NAUSEA AND VOMITING; NOCICEPTION; PAIN ASSESSMENT; PHARMACOGENETICS; POSTOPERATIVE PAIN; REVIEW;

ACUTE DISEASE; ANALGESICS; CHRONIC DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; PAIN, POSTOPERATIVE; PHARMACOGENETICS;

EID: 78649491891     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Kehlet H, Holte K. Effect of postoperative analgesia on surgical outcome. Br J Anaesth 2001;87:62-72.
2. Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth 1997;78:606-17.
3. Fanelli G, Berti M, Baciarello M. Updating postoperative pain management: from multimodal to context-sensitive treatment. Minerva Anestesiol 2008;74:489-500.
4. Buvanendran A, Kroin JS. Multimodal analgesia for controlling acute postoperative pain. Curr Opin Anaesthesiol 2009;22:588-93.
5. Viscusi ER. Patient-controlled drug delivery for acute postoperative pain management: a review of current and emerging technologies. Reg Anesth Pain Med 2008;33:146-58.
6. Hudcova J, McNicol E, Quah C, Lau J, Carr DB. Patient controlled opioid analgesia versus conventional opioid analgesia for postoperative pain. Cochrane Database Syst Rev 2006;18:CD003348.
7. Allegri M, Grossi P,Ferrari F, Borghi B. Regional anaesthesia and side effects: is it safe? Eur J Pain 2008;2(Suppl 1):31-35.
8. Joshi GP, Bonnet F, Shah R, Wilkinson RC, Camu F, Fischer B et al. A systematic review of randomized trials evaluating regional techniques for postthoracotomy analgesia. Anesth Analg 2008;107:1026-40.
9. Capdevila X, Ponrouch M, Choquet O. Continuous peripheral nerve blocks in clinical practice. Curr Opin Anaesthesiol 2008;21:619-23.
10. Hanna MN, Murphy JD, Kumar K, Wu CL. Regional techniques and outcome: what is the evidence? Curr Opin Anaesthesiol 2009;22:672-7.
11. Coluzzi F, Savoia G, Paoletti F, Costantini A, Mattia C. Postoperative pain survey in Italy (POPSI): a snapshot of current national practices. Min Anestesiol 2009;75:622-31.
12. Allegri M. Postoperative pain in Italy: an update. Minerva Anestesiol 2009;75:604-6.
13. Benhamou D, Berti M, Brodner G, De Andres J, Draisci G, Moreno-Azcoita M et al. Postoperative Analgesic Therapy Observational Survey (PATHOS): A practice pattern study in 7 central/ southern European countries. Pain 2008;136:134-41.
14. White PF, Kehlet H. Improving postoperative pain management. what are the unresolved issues? Anesthesiology 2010;112:220-5.
15. Werner MU, Duun P, Kehlet H. Prediction of postoperative pain by preoperative nociceptive responses to heat stimulation. Anesthesiology 2004;100:115-9.
16. Max MB, Stewart WF. The molecular epidemiology of pain: A new discipline for drug discovery. Nat Rev Drug Discov 2008;7:647-58.
17. Landau R, Kraft JC, Flint LY, Carvalho B, Richebé P, Cardoso M et al. An experimental paradigm for the prediction of Post-Operative Pain (PPOP). vbVis Exp 201027;(35). pii: 1671. doi: 10.3791/1671.
18. Diatchenko L, Nackley AG, Tchivileva IE, Shabalina SA, Maixner W. Genetic architecture of human pain perception. Trends Genet 2007;23:605-13.
19. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007;81:429-44.
20. Argoff CE. Clinical implications of opioid pharmacogenetics. Clin J Pain 2010;26 Suppl 10:S16-20.
21. Katz J, Seltzer Z. Transition from acute to chronic postsurgical pain: risk factors and protective factors. Expert Rev Neurother 2009;9:723-44.
22. Lynch EP, Lazor MA, Gellis JE, Orav J, Goldman L, Marcantonio ER. Patient experience of pain after elective noncardiac surgery. Anesth Analg. 1997;85:117-23.
23. Govoni S, Regazzi M, Ranzani GN. Pain and the pharmacogenetics at the fuzzy border between pain physiopathology and pain treatment Eur J Pain 2008;2(Suppl 1):5-12.
24. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995;34:4202-10.
25. Rakvåg TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005;116:73-8.
26. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005;14:135-43.
27. Diatchenko L, Nackley AG, Slade GD, Bhalang K, Belfer I, Max MB et al. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 2006;125:216-24.
28. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet 2006;367:1618-25.
29. Burke S, Shorten GD. When pain after surgery doesn't go away.... Biochem Soc Trans 2009;37:318-22.
30. Kato K, Sullivan PF, Evengård B, Pedersen NL. Importance of genetic influences on chronic widespread pain. Arthritis Rheum 2006;54:1682-6.
31. Wildgaard K, Iversen M, Kehlet H. Chronic pain after lung transplantation: a nationwide study. Clin J Pain. 2010;26:217-22.
32. Aasvang EK, Gmaehle E, Hansen JB, Gmaehle B, Forman JL, Schwarz J et al. Predictive risk factors for persistent postherniotomy pain. Anesthesiology 2010;112:957-69.
33. Gärtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 2009;302:1985-92.
34. Tegeder I, Costigan M, Griffin RS, Abele A, Belfer I, Schmidt H et al. CJ. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med 2006;12:1269-77.
35. Holliday KL, Nicholl BI, Macfarlane GJ, Thomson W, Davies KA, McBeth J. Do genetic predictors of pain sensitivity associate with persistent widespread pain? Mol Pain 2009;5:56.
36. Shabalina SA, Zaykin DV, Gris P, Ogurtsov AY, Gauthier J, Shibata K et al. Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum Mol Genet 2009;18:1037-51.
37. Diatchenko L, Anderson AD, Slade GD, Fillingim RB, Shabalina SA, Higgins TJ et al. W. Three major haplotypes of the beta2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder. Am J Med Genet B Neuropsychiatr Genet 2006;141:449-62.
38. Hocking LJ, Smith BH, Jones GT, Reid DM, Strachan DP, Macfarlane GJ. Genetic variation in the beta2-adrenergic receptor but not catecholamine-O-methyltransferase predisposes to chronic pain: Results from the 1958 British Birth Cohort Study. Pain 2010;149:143-51.
39. Kasai S, Hayashida M, Sora I, Ikeda K. Candidate gene polymorphisms predicting individual sensitivity to opioids. Naunyn Schmiedebergs Arch Pharmacol 2008;377:269-81.
40. Lötsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 2005;11:82-9.
41. Lötsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004;43:983-1013.
42. Lötsch J, Geisslinger G. Current evidence for a genetic modulation of the response to analgesics. Pain 2006;121:1-5.
43. Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006;50:787-92.
44. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006;105:334-7.
45. Klepstad P, Rakvåg TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004;48:1232-9.
46. Sia AT, Lim Y, Lim EC, Goh RW, Law HY, Landau R et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008;109:520-6.
47. Hayashida M, Nagashima M, Satoh Y, Katoh R, Tagami M, Ide S et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 2008;9:1605-16.
48. Conroy JL, Fang C, Gu J, Zeitlin SO, Yang W, Yang J et al. Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. Nat Neurosci 2010;13:284-6.
49. Coulbault L, Beaussier M, Verstuyft C, Weickmans H, Dubert L, Trégouet D et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 2006;79:316-24
50. Coller JK, Christrup LL, Somogyi AA. Role of active metabolites in the use of opioids. Eur J Clin Pharmacol 2009;65:121-39.
51. Hara Y, Nakajima M, Miyamoto K, Yokoi T Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine. Drug Metab Pharmacokinet 2007;22:103-12.
52. Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J. UGT2B7 promoter variant-840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 2008;83:200-2.
53. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009;48:689-723.
54. Howard S, Smith MD. Opioid Metabolism. Mayo Clin Proc 2009;84:613-24.
55. Lötsch J, Skarke C, Tegeder I, Geisslinger G. Drug interactions with patient-controlled analgesia. Clin Pharmacokinet 2002;41:31-57.
56. Lötsch J, Geisslinger G, Tegeder I. Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther 2009;124:168-84.
57. Choi MK, Song IS. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 2008;23:243-53.
58. Ranzani GN, De Gregori S, De Gregori M, Regazzi M, Govoni S. Interindividual variability of drug transporters: Impact on opioid treatment in chronic renal failure. Eur J Pain 2009;3(Suppl 2):21-8.
59. Zhu W, Cadet P, Baggerman G, Mantione KJ, Stefano GB. Human white blood cells synthesize morphine: CYP2D6 modulation. J Immunol 2005;175:7357-62.
60. Candiotti KA, Yang Z, Rodriguez Y, Crescimone A, Sanchez GC, Takacs P et al. The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption. Pain Med 2009;10:799-805.
61. Kosarac B, Fox AA, Collard CD. Effect of genetic factors on opioid action. Curr Opin Anaesthesiol 2009;22:476-82.
62. Reyes-Gibby CC, Shete S, Rakvåg T, Bhat SV, Skorpen F, Bruera E et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007;130:25-30.
63. Toide K, Takahashi Y, Yamazaki H, Terauchi Y, Fujii T, Parkinson A et al. Hepatocyte nuclear factor-1alpha is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers. Drug Metab Dispos 2002;30:613-5.
64. De Gregori M, Allegri M, De Gregori S, Garbin G, Tinelli C, Regazzi M et al. How and why to screen for cyp2d6 interindividual variability in patients under pharmacological treatments. Curr Drug Metab 2010;11:276-82.